Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Sanofi was a detractor this quarter. A run of...
— Oldfield Partners LLP
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Sanofi
Sanofi's strong fundamentals and core asset Dupixent are undervalued due to temporary vaccine market volatility and patent cliff anxieties. The manager bought...
Market concerns over a potential vaccine critic heading the US HHS caused an industry-wide sell-off, which the manager believes is an overreaction for Sanofi given its vaccine division's small revenue share. The pipeline for...
More institutional theses from Oldfield Partners Overstone Global Large Cap
The Swatch Group ($UHR.SW) is a Switzerland-based global manufacturer and distributor of finished watches, jewelry, and watch movements across luxury and mass-market segments. The manager maintains...
Ally Financial ($ALLY) is a prominent US digital financial services company focused primarily on automotive lending and direct digital banking. The fund manager...
L) is a major European low-cost carrier providing point-to-point passenger airline travel. The manager is...